AGRX:NSD-Agile Therapeutics, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 1.51

Change

-0.21 (-11.95)%

Market Cap

USD 0.15B

Volume

4.00M

Average Target Price

USD 9.33 (+518.10%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CGC Canopy Growth Corporation

-0.21 (-0.82%)

USD9.81B N/A N/A
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
TLRY Tilray, Inc

-0.20 (-1.24%)

USD5.10B N/A N/A
APHA Tilray, Inc

-0.20 (-1.24%)

USD4.87B 60.60 454.68
CRON Cronos Group Inc

-0.07 (-0.88%)

USD2.95B 37.00 N/A
PCRX Pacira BioSciences, Inc

+0.24 (+0.39%)

USD2.72B 18.53 44.09
ORGO Organogenesis Holdings Inc

+0.52 (+2.48%)

USD2.68B 130.88 76.89
IRWD Ironwood Pharmaceuticals, Inc

N/A

USD1.75B 16.41 13.31
SUPN Supernus Pharmaceuticals, Inc

+0.39 (+1.30%)

USD1.60B 12.75 7.62

ETFs Containing AGRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.39% 3% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.39% 3% F 3% F
Trailing 12 Months  
Capital Gain -38.62% 14% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.62% 14% F 5% F
Trailing 5 Years  
Capital Gain -74.28% 18% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.28% 18% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain 36.92% 86% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.92% 86% B 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 119.24% 14% F 12% F
Risk Adjusted Return 30.97% 81% B- 52% F
Market Capitalization 0.15B 27% F 27% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.31 57% F 48% F
Price / Cash Flow Ratio -3.20 42% F 63% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -109.08% 24% F 10% F
Return on Invested Capital -87.89% 8% F 9% F
Return on Assets -50.01% 7% F 5% F
Debt to Equity Ratio 33.21% 53% F 51% F
Technical Ratios  
Short Ratio 2.85 62% D- 47% F
Short Percent 6.75% 52% F 31% F
Beta 1.05 68% D+ 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.